Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRV043
MIFTS: 46

Cervical Dystonia

Categories: Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cervical Dystonia

About this section

MalaCards integrated aliases for Cervical Dystonia:

Name: Cervical Dystonia 12 54 38 15
Spasmodic Torticollis 12 77 54

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0050840
KEGG 38 H01608
ICD10 34 G24.3
Sources

Summaries for Cervical Dystonia

About this section
NIH Rare Diseases : 54 Cervical dystoniais a neurological condition characterized by excessive pulling of the muscles of the neck and shoulder resulting in abnormal movements of the head (dystonia). Most commonly, the head turns to one side or the other. Tilting sideways, or to the back or front may also occur. The turning or tilting movements may be accompanied by shaking movement (tremor) and/or soreness of the muscles of the neck and shoulders. Cervical dystonia can occur at any age, but most cases occur in middle age. It often begins slowly and usually reaches a plateau over a few months or years. The cause of cervical dystonia is often unknown. In some cases there is a family history. Several genes have been associated with cervical dystonia, including GNAL, THAP1, CIZ1, and ANO3. Other cases may be linked to an underlying disease (e.g. Parkinson disease), neck trauma, or certain medications. Treatment may include local injections of botulinum toxin, pain medications, benzodiazepines (anti-anxiety medications), anticholinergics, physical therapy, or surgery.

MalaCards based summary : Cervical Dystonia, also known as spasmodic torticollis, is related to dystonia 24 and dystonia 11, myoclonic. An important gene associated with Cervical Dystonia is CIZ1 (CDKN1A Interacting Zinc Finger Protein 1), and among its related pathways/superpathways are ICos-ICosL Pathway in T-Helper Cell and Tuberculosis. The drugs Acetylcholine and Botulinum Toxins have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related phenotypes are behavior/neurological and mortality/aging

Disease Ontology : 12 A focal dystonia that is characterized by simultaneous contraction of the agonist and antagonist muscles that control the position of the head contracting during dystonic movement which causes the neck to involuntarily turn to the left, right, upwards, and/or downwards.

Wikipedia : 77 Spasmodic torticollis is an extremely painful chronic neurological movement disorder causing the neck to... more...

Sources

Related Diseases for Cervical Dystonia

About this section

Diseases related to Cervical Dystonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 120)
# Related Disease Score Top Affiliating Genes
1 dystonia 24 32.1 THAP1 TOR1A
2 dystonia 11, myoclonic 31.2 CAMP GCH1 THAP1 TOR1A
3 torticollis 30.8 CIZ1 TOR1A
4 dystonia 30.7 CIZ1 DRD5 GCH1 GNAL THAP1 TOR1A
5 spasmodic dysphonia 30.1 THAP1 TOR1A
6 dystonia 12 29.3 CAMP GCH1 THAP1 TOR1A
7 blepharospasm 29.3 CAMP DRD5 GCH1 GNAL THAP1 TOR1A
8 focal hand dystonia 29.0 CAMP DRD5 THAP1 TOR1A
9 spasmodic dystonia 29.0 CAMP GNAL THAP1 TOR1A
10 focal dystonia 27.7 CAMP CDIP1 CIZ1 DRD5 GNAL THAP1
11 dystonia 23 11.7
12 leukoencephalopathy with dystonia and motor neuropathy 11.5
13 dyt-gnal 11.5
14 lymphatic malformation 5 11.4
15 x-linked dystonia-parkinsonism/lubag 11.2
16 dystonia 7, torsion 11.1
17 torsion dystonia 4 11.1
18 dyt-thap1 11.1
19 dyt-tubb4a 11.1
20 benign paroxysmal torticollis of infancy 10.5
21 tremor 10.5
22 achalasia, familial esophageal 10.3 HLA-DQA1 HLA-DQB1
23 beryllium disease 10.3 HLA-DQA1 HLA-DQB1
24 alexithymia 10.2
25 social phobia 10.2
26 neuropathy 10.2
27 idiopathic bronchiectasis 10.2 HLA-DQA1 HLA-DQB1
28 congenital toxoplasmosis 10.2 HLA-DQA1 HLA-DQB1
29 autosomal dominant cerebellar ataxia 10.2
30 essential tremor 10.2
31 acute disseminated encephalomyelitis 10.2 HLA-DQA1 HLA-DQB1
32 oligoarticular juvenile idiopathic arthritis 10.2 HLA-DQA1 HLA-DQB1
33 endometritis 10.2 HLA-DQA1 HLA-DQB1
34 immunoglobulin alpha deficiency 10.2 HLA-DQB1 TOR1A
35 ataxia and polyneuropathy, adult-onset 10.1
36 dysphagia 10.1
37 kleine-levin hibernation syndrome 10.1 HLA-DQB1 TOR1A
38 headache 10.1
39 hemifacial spasm 10.1
40 thiamine metabolism dysfunction syndrome 2 10.1 GCH1 TOR1A
41 tetralogy of fallot 10.1
42 tardive dyskinesia 10.1
43 thrombosis 10.1
44 disease of mental health 10.1
45 thoracic outlet syndrome 10.1
46 neurotic disorder 10.1
47 acquired immunodeficiency syndrome 10.1
48 narcolepsy 10.1
49 athetosis 10.1
50 cytomegalovirus infection 10.1

Graphical network of the top 20 diseases related to Cervical Dystonia:



Diseases related to Cervical Dystonia
Sources

Symptoms & Phenotypes for Cervical Dystonia

About this section

MGI Mouse Phenotypes related to Cervical Dystonia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.56 BDNF CIZ1 DRD5 GNAL HLA-DQB1 NALCN
2 mortality/aging MP:0010768 9.28 BDNF CAMP DRD5 GCH1 GNAL HLA-DQB1
Sources

Drugs & Therapeutics for Cervical Dystonia

About this section

Drugs for Cervical Dystonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
2 Botulinum Toxins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
4 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Neuromuscular Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
7 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
8 abobotulinumtoxinA Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
9 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
11 rimabotulinumtoxinB Phase 4,Phase 2
12 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
13 Antihypertensive Agents Phase 2, Phase 3
14 Vasodilator Agents Phase 2, Phase 3
15
Dronabinol Approved, Illicit Phase 2 1972-08-3 16078
16
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
17
Amlodipine Approved Phase 2 88150-42-9 2162
18
Levetiracetam Approved, Investigational Phase 2 102767-28-2 441341
19
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
20 Hormone Antagonists Phase 2
21 Cannabinoid Receptor Agonists Phase 2
22 Hormones Phase 2
23 Analgesics, Non-Narcotic Phase 2,Phase 1
24 Analgesics Phase 2,Phase 1
25 Psychotropic Drugs Phase 2
26 Hallucinogens Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
28 Gastrointestinal Agents Phase 1, Phase 2
29 Antirheumatic Agents Phase 1, Phase 2
30 Anti-Inflammatory Agents Phase 1, Phase 2,Not Applicable
31 Immunosuppressive Agents Phase 1, Phase 2
32 Immunologic Factors Phase 1, Phase 2
33 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
34 Autoantibodies Phase 1, Phase 2
35 calcium channel blockers Phase 2
36 Calcium, Dietary Phase 2
37 Anticonvulsants Phase 2
38 Nootropic Agents Phase 2
39
Trihexyphenidyl Approved 144-11-6, 58947-95-8 5572
40
Triamcinolone Approved, Vet_approved Not Applicable 124-94-7 31307
41
Methylprednisolone Approved, Vet_approved Not Applicable 83-43-2 6741
42
Methylprednisolone hemisuccinate Approved Not Applicable 2921-57-5
43
Prednisolone phosphate Approved, Vet_approved Not Applicable 302-25-0
44
Prednisolone Approved, Vet_approved Not Applicable 50-24-8 5755
45
Cortisone Experimental Not Applicable 53-06-5 222786
46
Prednisolone hemisuccinate Experimental Not Applicable 2920-86-7
47 Muscarinic Antagonists
48 Cholinergic Antagonists
49 Antiparkinson Agents
50 Triamcinolone hexacetonide Not Applicable

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
2 Botox for Cervical Dystonia Following EMG Mapping Completed NCT00773253 Phase 4 Botulinum toxin A
3 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia Completed NCT00950664 Phase 4 Dysport® (abobotulinumtoxinA);Botox® (onabotulinumtoxinA)
4 An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia Completed NCT00702754 Phase 4
5 Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex Completed NCT01486264 Phase 4
6 Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia Completed NCT00541905 Phase 4 NT 201
7 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
8 Neurotoxin and Physical Therapy Completed NCT02177617 Phase 4 Botox injection
9 Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia Completed NCT01384214 Phase 4
10 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia Completed NCT00528541 Phase 4
11 Functional Effects of Botox on the Brain Using MRS and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
12 OnabotulinumtoxinA in the Management of Psychogenic Dystonia Completed NCT02618889 Phase 4
13 Frontalis Botulinum Toxin Not yet recruiting NCT03186001 Phase 4 Abobotulinum toxin A
14 Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia Terminated NCT00432341 Phase 4
15 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Unknown status NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
16 Efficacy and Safety of MEDITOXIN® in Cervical Dystonia Completed NCT03905304 Phase 3
17 Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia Completed NCT00447772 Phase 3 Botulinum type A toxin (Dysport®)
18 Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia. Completed NCT01753310 Phase 3 Dysport®;Placebo
19 Study Comparing Short Term Efficacy of Dysport® and Dysport RU® to Placebo, and to Assess Efficacy and Safety of Dysport RU® of Subjects With Cervical Dystonia Completed NCT01261611 Phase 3 Botulinum type A toxin (Dysport RU®);Botulinum type A toxin (Dysport®);Placebo
20 Double-blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia Completed NCT00148889 Phase 3
21 Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia Completed NCT01753336 Phase 3 Dysport®
22 Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Completed NCT00288509 Phase 3 abobotulinumtoxinA (Dysport) 250-1000 units
23 Meditoxin® Treatment in Patients With Cervical Dystonia Completed NCT03232320 Phase 3 Meditoxin;Placebo
24 Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Completed NCT00257660 Phase 3 Botulinum type A toxin (Dysport®);Placebo
25 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia Completed NCT00407030 Phase 3 incobotulinumtoxinA (Xeomin) (240 Units);incobotulinumtoxinA (Xeomin) (120 Units);Placebo
26 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Completed NCT02604186 Phase 2, Phase 3
27 Addressing Involuntary Movements in Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
28 Aim to Reduce Movements in Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
29 Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1) Recruiting NCT03608397 Phase 3
30 Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS) Recruiting NCT03617367 Phase 3
31 Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia Not yet recruiting NCT03805152 Phase 3 Neuronox(R);Dysport (R)
32 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Withdrawn NCT03254186 Phase 2, Phase 3 Propranolol Hydrochloride;Placebo Oral Tablet
33 ASIS for Botox in Cervical Dystonia Unknown status NCT02074293 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Botox intramuscularly at Week 6;Efficacy of Botox intramuscularly at Week 12;Efficacy of Botox intramuscularly at Week 18;Efficacy of Botox intramuscularly at Week 24;Efficacy of Botox intramuscularly at Week 30;Efficacy of Botox subdermally at Week 6;Efficacy of Botox subdermally at Week 12;Efficacy of Botox subdermally at Week 18;Efficacy of Botox subdermally at Week 24;Efficacy of Botox subdermally at Week 30;Adverse Reactions of Botox intramuscularly;Adverse Reactions of Botox subdermally
34 Efficacy of Dronabinol for the Treatment of Cervical Dystonia Unknown status NCT00418925 Phase 2 Dronabinol
35 Study of the Treatment of Tendinopathy Unruptured of Rotator Cuff by Intramuscular Injection of Botulinum Toxin Unknown status NCT02867787 Phase 2 Botox arm
36 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
37 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia Completed NCT00564681 Phase 2 Normal Saline
38 Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain Completed NCT00178945 Phase 1, Phase 2 Botulinum Toxin Type A
39 Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis Completed NCT00165776 Phase 2 BOTULINUM TOXIN TYPE B
40 Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia Completed NCT02706795 Phase 2
41 Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia Completed NCT01588574 Phase 2
42 Amlodipine Plus Botulinum Toxin for Focal Dystonia Completed NCT00015457 Phase 2 Amlodipine plus Botulinum toxin
43 Deep Brain Stimulation for Cervical Dystonia Completed NCT00105430 Phase 2
44 An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects Completed NCT00280384 Phase 2 E2014 (Botulinum toxin type B);E2014 (Botulinum toxin type B) Placebo
45 Clinical and Kinematic Assessment for Determination of Botox® Injection Parameters in Cervical Dystonia Recruiting NCT02662530 Phase 2 Botulinum Toxin Type A
46 Safety and Tolerability of Perampanel in Cervical Dystonia Recruiting NCT02131467 Phase 1, Phase 2 Perampanel
47 Keppra for Cervical Dystonia Terminated NCT00760318 Phase 2 Keppra
48 Botulinum Toxin Injection Efficiency Unknown status NCT01041157 Phase 1
49 PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia Completed NCT00549341 Phase 1 Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin
50 Deep Brain Stimulation to Treat Cervical Dystonia Completed NCT00132340 Phase 1

Search NIH Clinical Center for Cervical Dystonia

Sources

Genetic Tests for Cervical Dystonia

About this section
Sources

Anatomical Context for Cervical Dystonia

About this section

MalaCards organs/tissues related to Cervical Dystonia:

42
Brain, Spinal Cord, Testes, Cerebellum, Globus Pallidus, Cortex, T Cells
Sources

Publications for Cervical Dystonia

About this section

Articles related to Cervical Dystonia:

(show top 50) (show all 1108)
# Title Authors Year
1
Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives. ( 30659417 )
2019
2
Oropharyngeal Dysphagia in Adults With Dyskinetic Cerebral Palsy and Cervical Dystonia: A Preliminary Study. ( 29958905 )
2019
3
A Novel Missense OPA1 Mutation in a Patient with Dominant Optic Atrophy and Cervical Dystonia. ( 30838318 )
2019
4
Secondary Cervical Dystonia and Titubatory Head Tremor. ( 30838321 )
2019
5
Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance. ( 30859009 )
2019
6
Neural Correlates of Abnormal Temporal Discrimination in Unaffected Relatives of Cervical Dystonia Patients. ( 30914929 )
2019
7
Pain in cervical dystonia and the antinociceptive effects of botulinum toxin: what is currently known? ( 30917105 )
2019
8
Cause or effect: Altered brain and network activity in cervical dystonia is partially normalized by botulinum toxin treatment. ( 30928809 )
2019
9
Increased Finger-Tapping Related Cerebellar Activation in Cervical Dystonia, Enhanced by Transcranial Stimulation: An Indicator of Compensation? ( 30930842 )
2019
10
Specific characteristics of the medical history of swallowing before and after application of botulinum toxin in patients with cervical dystonia. ( 30942281 )
2019
11
Maladaptive striatal plasticity and abnormal reward-learning in cervical dystonia. ( 30955204 )
2019
12
White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment. ( 31019484 )
2019
13
Head tremor at disease onset: an ataxic phenotype of cervical dystonia. ( 31028543 )
2019
14
Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice. ( 31049731 )
2019
15
Network localization of cervical dystonia based on causal brain lesions. ( 31099831 )
2019
16
Author's Response to Letter to the Editor on "Ultrasound-Guided Botulinum Toxin Injections in Cervical Dystonia Needs Prompt Muscle Selection, Appropriate Dosage, and Precise Guidance". ( 30096053 )
2019
17
Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport® ). ( 30168896 )
2019
18
Ultrasound-Guided Botulinum Toxin Injections in Cervical Dystonia Needs Prompt Muscle Selection, Appropriate Dosage, and Precise Guidance. ( 30198913 )
2019
19
Deep Brain Stimulation Versus Peripheral Denervation for Cervical Dystonia: A Systematic Review and Meta-Analysis. ( 30419402 )
2019
20
Cervical dystonia in a case of longstanding secondary progressive multiple sclerosis. ( 30612702 )
2019
21
The role of pallidum in the neural integrator model of cervical dystonia. ( 30677494 )
2019
22
Abnormal cerebellar connectivity and plasticity in isolated cervical dystonia. ( 30682155 )
2019
23
The effect of CT-guided botulinum toxin injection on cervical dystonia, confirmed by nine-month follow-up using 18F-FDG PET/CT : A case report. ( 30741760 )
2019
24
Long-term specialized physical therapy in cervical dystonia: outcomes of a randomized controlled trial. ( 30796919 )
2019
25
A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia. ( 30837195 )
2019
26
Brachial Neuritis After Botulinum Toxin Injections for Cervical Dystonia: A Need for a Reappraisal? ( 30838316 )
2019
27
Microvascular decompression with partial occipital condylectomy in a case of pediatric spasmodic torticollis. ( 30701298 )
2019
28
Improvement of quality of life and mental health in patients with spasmodic torticollis after microvascular decompression. ( 30933844 )
2019
29
Sexual dysfunction in cervical dystonia and blepharospasm. ( 30464469 )
2018
30
Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy. ( 29772695 )
2018
31
Biased Visuospatial Attention in Cervical Dystonia. ( 28791940 )
2018
32
Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? ( 28888929 )
2018
33
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. ( 28891721 )
2018
34
Adaptation of feedforward movement control is abnormal in patients with cervical dystonia and tremor. ( 28943258 )
2018
35
Motor Cortical Plasticity Relates to Symptom Severity and Clinical Benefit From Deep Brain Stimulation in Cervical Dystonia. ( 28961350 )
2018
36
Is perception of visual verticality intact in patients with idiopathic cervical dystonia? ( 29101737 )
2018
37
Selective Cervical Denervation for Cervical Dystonia: Modification of the Bertrand Procedure. ( 29106650 )
2018
38
Sonographic Guide for Botulinum Toxin Injections of the Neck Muscles in Cervical Dystonia. ( 29173657 )
2018
39
Speech induced cervical dystonia: An unusual task specific dystonia. ( 29174183 )
2018
40
The premotor syndrome of cervical dystonia: Disordered processing of salient environmental stimuli. ( 29205495 )
2018
41
INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. ( 29270685 )
2018
42
Cortical inhibitory function in cervical dystonia. ( 29311009 )
2018
43
Physiological effects of subthalamic nucleus deep brain stimulation surgery in cervical dystonia. ( 29326293 )
2018
44
Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor. ( 29326295 )
2018
45
Postural control and the relation with cervical sensorimotor control in patients with idiopathic adult-onset cervical dystonia. ( 29340715 )
2018
46
A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. ( 29343142 )
2018
47
Abnormal cerebellar processing of the neck proprioceptive information drives dysfunctions in cervical dystonia. ( 29396401 )
2018
48
Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia. ( 29443021 )
2018
49
Sertraline induced cervical dystonia in a patient of Obsessive Compulsive Disorder. ( 29447992 )
2018
50
Pedunculopontine Nucleus Cholinergic Deficiency in Cervical Dystonia. ( 29508906 )
2018
Sources

Variations for Cervical Dystonia

About this section
Sources

Expression for Cervical Dystonia

About this section
Search GEO for disease gene expression data for Cervical Dystonia.
Sources

Pathways for Cervical Dystonia

About this section

Pathways related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
ICos-ICosL Pathway in T-Helper Cell 65
Show member pathways
 11.81 GNAL HLA-DQA1 HLA-DQB1
2
Tuberculosis 38
11.38 CAMP HLA-DQA1 HLA-DQB1
3
DNA damage_Role of Brca1 and Brca2 in DNA repair 23
10.93 GNAL HLA-DQA1 HLA-DQB1
4
CTLA4 Signaling 65
10.65 GNAL HLA-DQA1 HLA-DQB1
Sources

GO Terms for Cervical Dystonia

About this section

Cellular components related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transport vesicle membrane GO:0030658 9.26 HLA-DQA1 HLA-DQB1
2 clathrin-coated endocytic vesicle membrane GO:0030669 9.16 HLA-DQA1 HLA-DQB1
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-DQA1 HLA-DQB1
4 MHC class II protein complex GO:0042613 8.62 HLA-DQA1 HLA-DQB1

Biological processes related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation GO:0019882 9.26 HLA-DQA1 HLA-DQB1
2 negative regulation of blood pressure GO:0045776 9.16 DRD5 GCH1
3 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 8.96 HLA-DQA1 HLA-DQB1
4 regulation of protein localization to cell surface GO:2000008 8.62 BDNF TOR1A

Molecular functions related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.96 HLA-DQA1 HLA-DQB1
2 MHC class II receptor activity GO:0032395 8.62 HLA-DQA1 HLA-DQB1
Sources

Sources for Cervical Dystonia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....